Showing posts with label acute coronary syndrome. Show all posts
Showing posts with label acute coronary syndrome. Show all posts

Wednesday, July 17, 2019

Aspiring desensitization therapy is safe and effective in patients with acute coronary syndrome



New research suggests that acetylsalicylic acid (ASA) desensitization therapy is safe and effective in patients with acute coronary syndrome (ACS). The meta-analysis published July 1, 2019 in the American Journal of Cardiology found that 98% of the patients were able to complete an aspirin-introduction protocol and continue aspirin until discharge, without symptoms of hypersensitivity.

After a PubMed database search, 15 reports consisting of 480 ACS patients with previous hypersensitivity to ASA were included in the meta-analysis. The primary end point was desensitization protocol success. Hypersensitivity adverse events and ASA discontinuation due to hypersensitivity adverse events at follow-up were the secondary end points.

·         The pooled desensitization success rate was 98.3% (95% confidence interval: 97.2% to 99.5%). There was no statistical difference in outcomes between protocols ≤ 2 hours and > 2 hours in duration (96.3[92.3 to 100.3]% vs 97.2 [94.6 to 99.8]%; p = 0.71).
·         Protocols with > 6 dose escalations were associated with higher success rates compared to those with ≤ 6 doses (99.2[97.9 to 100.4]% vs 95.4[93 to 97.8]%; p = 0.007).
·         Zero hypersensitivity adverse events were reported at follow-up between 1 and 46 months. Consequently, no ASA discontinuations were related to hypersensitivity adverse events.

According to the study, protocols with > 6 dose escalations may be optimal for ASA desensitization in ACS patients.

(Source: Uptodate; Am J Cardiol. 2019 Jul 1;124(1):14-19)

Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA




Sunday, December 30, 2018

The Top Cardiology Trials of 2018: ODYSSEY



Treatment with alirocumab, a PCSK9 inhibitor, reduced cardiovascular outcomes and all-cause deaths by 15% in patients with acute coronary syndrome (ACS) and higher-than-ideal atherogenic lipoprotein levels despite intensive or maximally tolerated statin therapy in the ODYSSEY trial.

The ODYSSEY trial was a 3-year multicenter, randomized, double-blind, placebo-controlled trial involving almost 19,000 patients who had had a previous ACS within 1 month to 1 year before enrollment. Their LDL-cholesterol level was at least 70 mg/dL, non−HDL cholesterol level was at least 100 mg/dL or an apolipoprotein B level was at least 80 mg/dL; they were on statin therapy at a high-intensity dose or at the maximum tolerated dose.

Patients were randomized to biweekly injections of alirocumab or placebo. The dose could be uptitrated if LDL-cholesterol <50mg/dL was not achieved.

After 2.8 years, alirocumab significantly reduced cardiovascular (CV) death, myocardial infarction (MI), stroke, or hospitalization (primary end point) from 11.1% in the placebo group to 9.5% in the alirocumab group. Mortality was also reduced with alirocumab from 4.1% in placebo group down to 3.5% in the alirocumab group.

The benefits were greater among patients who had a baseline LDL-cholesterol of ≥100 mg/dL, where there was a 3.4% absolute risk reduction vs patients who had a lower baseline level. In that subgroup, you would only have to treat about 30 people to prevent a MACE event and there was a 1.7% reduction in mortality.

ODYSSEY Outcomes is the second outcomes trial with a PCSK9 inhibitor to show a reduction in LDL-C and cardiovascular endpoints. The earlier FOURIER trial, which used a fixed dose of the PCSK9 inhibitor evolocumab, showed no mortality advantages. Compared with FOURIER, the ODYSSEY Outcomes trial enrolled a higher-risk group of patients, had a longer duration of follow-up (ranging from two to five years), involved a different dosing strategy and had a slightly different primary endpoint

(Source: N Engl J Med. 2018;379:2097-210; Medscape, ACC News)

Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA

Monday, May 28, 2018

Triggers and treatment approaches to acute heart failure differ worldwide




The first analysis of data from the International REPORT-HF show that triggers of acute heart failure and treatment approaches differ in different geographical regions of the world as also the drugs used as treatment.

While, ischemia/acute coronary syndrome (ACS)/infarction constituted 25.6% of cases of HF in the Southeast Asian region, nonadherence to diet and medications (19.2%) were the main cause in North America.

l In Southeast Asia, the other factors causing HF (in descending order) were nonadherence to diet and medications (5.4%), uncontrolled hypertension (5.2%), arrhythmia (4.7%) followed by pneumonia/respiratory process/infection (4.5%).

l Uncontrolled hypertension (8.2%), arrhythmia (7.6%), ischemia/ACS/infarction (3.5%) and pneumonia/respiratory process/infection (4.1%) were found to be the other triggers for HF in North America.

Treatment approaches also found to vary among the different regions globally.

l Inotropes were used more often in Southeast Asia Western Pacific, and Eastern Europe (11.3–13.5%) compared to other regions viz. Western Europe and North America (3.1–4.3%).

l The time between contacting medical services and receiving intravenous diuretics was 3.5 hours (average) in North American vs just over one hour in other regions. While, treatment with IV vasodilators within 6 hours of hospital contact was associated with a significantly shorter length of hospitalization across all regions, factors like renal function, systolic BP, signs of congestion on chest X-ray and cause of acute HF also influenced duration of hospital stay.

These results from the REPORT-HF registry were presented at the ongoing Heart Failure 2018 and the World Congress on Acute Heart Failure in Vienna, Austria.

Unlike other registries, the REPORT-HF (REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) is a dedicated HF global registry and collates data collected from patients in different regions of the world. The data compares regional differences in causes of acute heart failure, therapies, time to treatment and treatment outcomes in order to better understand the epidemiology of HF worldwide.

The Registry included 18,805 patients hospitalized with new‐onset (first diagnosis) heart failure (HF) or decompensation of chronic HF from 44 countries across seven regions: 1,622 patients in North America, 2,686 patients in Central and South America, 2,810 patients in Eastern Europe, 3,661 patients in Western Europe, 2,265 in the Eastern Mediterranean and Africa, 2,369 in Southeast Asia and 3,392 in the Western Pacific.

The median age of patients was 67 years, 52% were Caucasian, 31% were Asian, 5% were Black, and 61% were men.

(Source: ESC, May 26, 2018)


Dr KK Aggarwal
Padma Shri Awardee
Vice President CMAAO
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Immediate Past National President IMA